Literature DB >> 20142002

Vein wall remodeling after deep vein thrombosis: differential effects of low molecular weight heparin and doxycycline.

Vikram Sood1, Cathy Luke, Erin Miller, Mayo Mitsuya, Gilbert R Upchurch, Thomas W Wakefield, Dan D Myers, Peter K Henke.   

Abstract

BACKGROUND: Venous thrombus resolution sets up an early intense inflammatory reaction, from which vein wall damage results. Tissue response to injury includes matrix metalloproteinase (MMP) activation and extracellular matrix protein turnover. This study sought to determine the effect of exogenous MMP inhibition and its potential attenuation of early vein wall injury.
METHODS: Rats received treatment beginning 24 hr after a stasis venous thrombosis by near occlusive ligation and until harvest at day 7. Three groups were evaluated: (1) vehicle saline controls (NaCl), (2) low molecular weight heparin (LMWH; Lovenox, 3 mg/kg daily SQ), and (3) doxycycline (DOXY, 30 mg/kg daily PO). Thrombus size (mg/mm), levels of tumor necrosis factor alpha (TNF alpha) and D-dimer by colorimetric assay, and monocytes counts by immunohistochemistry were assessed. Vein wall assessment included stiffness by tensiometry, interleukin 1beta (IL-1 beta protein levels by enzyme-linked immunosorbent assay, MMP2 and -9 by zymography, and histological analysis of intimal thickness (IT). Comparisons were by t-test to control. p < 0.05 was considered significant.
RESULTS: Thrombus sizes were similar at days 2 and 7 for all three groups, while thrombus TNFalpha was increased in 2-day LMWH- and DOXY-treated groups (NaCl = 1.0 +/- 0.8, LWMH = 9 +/- 3, DOXY = 27 +/- 5 pg/mg protein, n = 6-8, p < 0.05) and at 7 days in the DOXY group (NaCl = 3.0 +/- 2.5, DOXY = 23 +/- 4.2 pg/mg protein, n = 5, p < 0.05). Vein wall stiffness at 7 days was less with LMWH treatment, but not with DOXY, compared to controls (NaCl = 0.33 +/- 0.05, LMWH = 0.17 +/- 0.03, DOXY = 0.43 +/- 0.09 N/mm, n = 5-7, p < 0.05). Vessel-wall IL-1 beta was reduced only in the DOXY group at 7 days (NaCl = 26 +/- 3, LMWH = 38 +/- 17, DOXY = 6 +/- 3 pg/mg protein, n = 4-6, p < 0.05), as was the IT score versus controls (NaCl = 2.2 +/- 0.6, LMWH =1.7 +/- 0.3, DOXY = 0.8 +/- 0.20, n = 4-6, p < 0.05). Zymographic MMP9 activity was significantly reduced at 2 days in the LMWH and DOXY groups (NaCl = 85 +/- 24, LMWH = 23 +/- 7( *), DOXY = 13 +/- 5 U/mg protein, n = 6-8, p < 0.05). MMP2 zymographic activity, thrombus monocyte cell counts, and D-dimer activity were not significantly different across groups.
CONCLUSION: Treatment with LMWH or DOXY did not alter the size of deep vein thrombosis, mildly altered thrombus composition, and differentially affected vein wall injury, despite similar reductions in early MMP9 activity. Whether exogenous MMP inhibition affects long-term vein wall fibrosis will require further study. Copyright 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20142002      PMCID: PMC2997482          DOI: 10.1016/j.avsg.2009.11.002

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  38 in total

1.  Doxycycline inhibition of interleukin-1 in the corneal epithelium.

Authors:  A Solomon; M Rosenblatt; D Q Li; Z Liu; D Monroy; Z Ji; B L Lokeshwar; S C Pflugfelder
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-08       Impact factor: 4.799

2.  Differential regulation of matrix metalloproteinase-9 by monocytes adherent to collagen and platelets.

Authors:  S W Galt; S Lindemann; D Medd; L L Allen; L W Kraiss; E S Harris; S M Prescott; T M McIntyre; A S Weyrich; G A Zimmerman
Journal:  Circ Res       Date:  2001-09-14       Impact factor: 17.367

3.  Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms.

Authors:  R Pyo; J K Lee; J M Shipley; J A Curci; D Mao; S J Ziporin; T L Ennis; S D Shapiro; R M Senior; R W Thompson
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

Review 4.  Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.

Authors:  Zorina S Galis; Jaikirshan J Khatri
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

5.  Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells.

Authors:  I Singh; K G Burnand; M Collins; A Luttun; D Collen; B Boelhouwer; A Smith
Journal:  Circulation       Date:  2003-02-18       Impact factor: 29.690

6.  Age-dependent impairment of reendothelialization after arterial injury: role of vascular endothelial growth factor.

Authors:  Giuseppa Gennaro; Catherine Ménard; Sophie-Elise Michaud; Alain Rivard
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

7.  Morphologic characteristics of varicose veins: possible role of metalloproteinases.

Authors:  Kenneth J Woodside; Mingdao Hu; Ann Burke; Maki Murakami; Lori L Pounds; Lois A Killewich; John A Daller; Glenn C Hunter
Journal:  J Vasc Surg       Date:  2003-07       Impact factor: 4.268

8.  Deep vein thrombosis resolution is impaired in diet-induced type 2 diabetic mice.

Authors:  Fatiha Bouzeghrane; Xiaochun Zhang; Guylaine Gevry; Jean Raymond
Journal:  J Vasc Surg       Date:  2008-10-01       Impact factor: 4.268

9.  Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins.

Authors:  Lianchun Wang; Jillian R Brown; Ajit Varki; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

10.  Effect of heparin and related glycosaminoglycan on PDGF-induced lung fibroblast proliferation, chemotactic response and matrix metalloproteinases activity.

Authors:  M Sasaki; M Kashima; T Ito; A Watanabe; M Sano; M Kagaya; T Shioya; M Miura
Journal:  Mediators Inflamm       Date:  2000       Impact factor: 4.711

View more
  9 in total

1.  Activated protein C accelerates venous thrombus resolution through heme oxygenase-1 induction.

Authors:  J Gabre; C Chabasse; C Cao; S Mukhopadhyay; S Siefert; Y Bi; S Netzel-Arnett; R Sarkar; L Zhang
Journal:  J Thromb Haemost       Date:  2014-01       Impact factor: 5.824

2.  Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis.

Authors:  Jose A Diaz; Nicole E Ballard-Lipka; Diana M Farris; Angela E Hawley; Shirley K Wrobleski; Daniel D Myers; Peter K Henke; Daniel A Lawrence; Thomas W Wakefield
Journal:  J Vasc Surg       Date:  2011-11-25       Impact factor: 4.268

3.  Enhanced venous thrombus resolution in plasminogen activator inhibitor type-2 deficient mice.

Authors:  S A Siefert; C Chabasse; S Mukhopadhyay; M H Hoofnagle; D K Strickland; R Sarkar; T M Antalis
Journal:  J Thromb Haemost       Date:  2014-09-30       Impact factor: 5.824

4.  The effect of matrix metalloproteinase 2 and matrix metalloproteinase 2/9 deletion in experimental post-thrombotic vein wall remodeling.

Authors:  Kristopher B Deatrick; Catherine E Luke; Megan A Elfline; Vikram Sood; Joseph Baldwin; Gilbert R Upchurch; Farouc A Jaffer; Thomas W Wakefield; Peter K Henke
Journal:  J Vasc Surg       Date:  2013-03-13       Impact factor: 4.268

5.  Recanalization and flow regulate venous thrombus resolution and matrix metalloproteinase expression in vivo.

Authors:  Christine Chabasse; Suzanne A Siefert; Mohammed Chaudry; Mark H Hoofnagle; Brajesh K Lal; Rajabrata Sarkar
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2014-05-10

6.  The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis.

Authors:  Joe F Baldwin; Vikram Sood; Megan A Elfline; Cathy E Luke; Nicholas A Dewyer; Jose A Diaz; Dan D Myers; Thomas Wakefield; Peter K Henke
Journal:  J Vasc Surg       Date:  2012-07-15       Impact factor: 4.268

7.  Matrix metalloproteinase-9 deletion is associated with decreased mid-term vein wall fibrosis in experimental stasis DVT.

Authors:  Kristopher B Deatrick; Andrea Obi; Catherine E Luke; Megan A Elfline; Vikram Sood; Gilbert R Upchurch; Farouc Jaffer; Thomas W Wakefield; Peter K Henke
Journal:  Thromb Res       Date:  2013-08-24       Impact factor: 3.944

8.  Matrix Metalloproteinase 9 (MMP-9) Regulates Vein Wall Biomechanics in Murine Thrombus Resolution.

Authors:  Khanh P Nguyen; Kirk C McGilvray; Christian M Puttlitz; Subhradip Mukhopadhyay; Christine Chabasse; Rajabrata Sarkar
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

9.  Novel microspheres reduce the formation of deep venous thrombosis and repair the vascular wall in a rat model.

Authors:  Bingyang Dai; Lan Li; Qiangqiang Li; Xiaoxiao Song; Dongyang Chen; Jin Dai; Yao Yao; Wenjin Yan; Huajian Teng; Fang Yang; Zhihong Xu; Qing Jiang
Journal:  Blood Coagul Fibrinolysis       Date:  2017-07       Impact factor: 1.276

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.